Loading people...
Keith Gottesdiener is a Venture Partner at Samsara BioCapital LLC based in Palo Alto, California. Before joining the firm, he served as Chief Executive Officer of Prime Medicine, Inc., where he oversaw its initial public offering, and previously spent nearly a decade as CEO of Rhythm Pharmaceuticals, Inc. At Rhythm, he led a $120 million IPO in 2017 and guided the clinical development and FDA approval of setmelanotide for three rare genetic obesity indications. Earlier in his career, he spent 16 years at Merck Research Laboratories as Worldwide Head of Late-Stage and Early Development, contributing to the approval of more than 20 novel therapeutics. He earned his medical degree from the University of Pennsylvania after studying applied mathematics. His current focus centers on advising life sciences portfolio companies and advancing therapeutics for rare genetic diseases.
Keith Gottesdiener serves as a highly respected Venture Partner at Samsara BioCapital, a leading venture capital firm dedicated to investing in groundbreaking life science companies. In this pivotal role, Dr. Gottesdiener leverages his profound industry knowledge and strategic insights to identify, evaluate, and support promising early-stage biotechnology ventures. His contributions are instrumental in guiding Samsara BioCapital's investment decisions, particularly in companies poised to revolutionize therapeutic development.
Dr. Gottesdiener's investment focus at Samsara BioCapital is deeply informed by his illustrious career in drug development and executive leadership. He is keenly interested in innovative therapeutics, drug discovery platforms, and companies addressing significant unmet medical needs, especially within rare diseases and metabolic disorders. His expertise extends across the entire spectrum of clinical development, from preclinical stages through regulatory approval and commercialization, making him an invaluable advisor to portfolio companies.
Before joining Samsara BioCapital, Dr. Gottesdiener held the position of Chief Executive Officer at Rhythm Pharmaceuticals from 2011 to 2022. During his tenure, he successfully led the company through its initial public offering and oversaw the development and regulatory approval of setmelanotide (Imcivree), a groundbreaking therapy for rare genetic forms of obesity. This achievement underscores his capability to navigate complex scientific and regulatory landscapes to bring life-changing medicines to patients.
Prior to Rhythm Pharmaceuticals, Dr. Gottesdiener spent over a decade at Merck & Co., Inc., where he held senior leadership roles, including Senior Vice President and Head of Worldwide Clinical Development from 1998 to 2011. In this capacity, he was responsible for overseeing clinical trials across all therapeutic areas, including cardiovascular, infectious diseases, oncology, neuroscience, and immunology. His leadership was critical in advancing numerous drugs through various stages of development, solidifying his reputation as a leader in pharmaceutical R&D.
Dr. Gottesdiener's career began in academic medicine, where he specialized in infectious diseases. He earned his medical degree from the University of Pennsylvania and completed his residency in Internal Medicine at Brigham and Women's Hospital, followed by a fellowship in Infectious Diseases at Massachusetts General Hospital. This robust medical and scientific foundation, combined with his extensive executive and development experience, positions Keith Gottesdiener as a formidable force in the biotechnology investment landscape, driving innovation and impact at Samsara BioCapital.
Keith Gottesdiener is a distinguished Venture Partner at Samsara BioCapital, renowned for his extensive background in pharmaceutical research, development, and executive leadership. He previously served as CEO of Rhythm Pharmaceuticals and held senior roles at Merck.
As a Venture Partner at Samsara BioCapital, Keith Gottesdiener focuses on investments in early-stage biotechnology companies. His expertise guides investments in drug discovery, clinical development, rare diseases, and metabolic disorders, aiming to support innovative therapeutic solutions.
Keith Gottesdiener works as a Venture Partner at Samsara BioCapital, a leading venture capital firm dedicated to investing in groundbreaking life science companies.
